Biomarkers of Inflammation and Fibrosis in Conduction Disorders After TAVI
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Clinical Hospital Center Rijeka
- Trial code
- NCT07201363
- Record updated
- 6 October 2025
- Original description
Prediction of conduction disorders (CDs) in patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve implantation (TAVI) is an important and complex process with a significant impact on patient outcomes. The goal of this observational prospective trial is to investigate the role of pre-procedural values of systemic biomarkers of inflammation and fibrosis in the prediction of new-onset CDs and permanent pacemaker implantation (PPI) in patients undergoing the TAVI procedure.Read full original descriptionShow less
The Role of Inflammation and Fibrosis in the Development of Conduction Disorders After Transcatheter Aortic Valve Implantation
Prediction of conduction disorders (CDs) in patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve implantation (TAVI) is an important and complex process with a significant impact on patient outcomes. The goal of this observational prospective trial is to investigate the role of pre-procedural values of systemic biomarkers of inflammation and fibrosis in the prediction of new-onset CDs and permanent pacemaker implantation (PPI) in patients undergoing the TAVI procedure.
Inclusion: Written consent to participate in the trial; Diagnosis of severe AS according to current European Society of Cardiology (ESC) guidelines for valvular heart disease.
Exclusion: Corticosteroid or other immunosuppressive therapy; Permanent pacemaker implanted previously; An acute myocardial infarction within three months before the procedure; A surgical procedure within three months before the procedure; Previous surgical or transcatheter aortic valve replacement/implantation; Acute infectious disease; Chronic inflammatory or autoimmune disease; Active malignant disease; Liver disease accompanied by dysfunction; End-stage chronic kidney disease (eGFR <15 ml/min).